Loss of ERβ expression as a common step in estrogen-dependent tumor progression

被引:346
作者
Bardin, A
Boulle, N
Lazennec, G
Vignon, F
Pujol, P
机构
[1] CHU Montpellier, Serv Biol Cellulaire, Hop Arnaud Villeneuve, Biol Cellulaire Lab, F-34295 Montpellier, France
[2] INSERM, Unite 540, F-34090 Montpellier, France
关键词
D O I
10.1677/erc.1.00800
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The characterization of estrogen receptor beta (ERbeta) brought new insight into the mechanisms underlying estrogen signaling. Estrogen induction of cell proliferation is a crucial step in carcinogenesis of gynecologic target tissues, and the mitogenic effects of estrogen in these tissues (such as breast, endometrium and ovary) are well documented both in vitro and in vivo. There is also an emerging body of evidence that colon and prostate cancer growth is influenced by estrogens. In all of these tissues, most studies have shown decreased ER expression in cancer as compared with benign tumors or normal tissues, whereas ERalpha expression persists. The loss of ERbeta expression in cancer cells could reflect tumor cell dedifferentiation but may also represent a critical stage in estrogen-dependent tumor progression. Modulation of the expression of ERa target genes by ERbeta or ERbeta-specific gene induction could explain that ERbeta has a differential effect on proliferation as compared with ERalpha. ERbeta may exert a protective effect and thus constitute a new target for hormone therapy, such as ligand specific activation. The potential distinct roles of ERalpha and ERbeta expression in carcinogenesis, as suggested by experimental and clinical data, are discussed in this review.
引用
收藏
页码:537 / 551
页数:15
相关论文
共 137 条
  • [31] Differential expression of estrogen receptor β (ERβ) and its C-terminal truncated splice variant ERβcx as prognostic predictors in human prostatic cancer
    Fujimura, T
    Takahashi, S
    Urano, T
    Ogawa, S
    Ouchi, Y
    Kitamura, T
    Muramatsu, M
    Inoue, S
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 289 (03) : 692 - 699
  • [32] Fuqua SAW, 2003, CANCER RES, V63, P2434
  • [33] Estrogenic diazenes: Heterocyclic non-steroidal Estrogens of unusual structure with selectivity for estrogen receptor subtypes
    Ghosh, U
    Ganessunker, D
    Sattigeri, VJ
    Carlson, KE
    Mortensen, DJ
    Katzenellenbogen, BS
    Katzenellenbogen, JA
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (04) : 629 - 657
  • [34] HUMAN ESTROGEN-RECEPTOR CDNA - SEQUENCE, EXPRESSION AND HOMOLOGY TO V-ERB-A
    GREEN, S
    WALTER, P
    KUMAR, V
    KRUST, A
    BORNERT, JM
    ARGOS, P
    CHAMBON, P
    [J]. NATURE, 1986, 320 (6058) : 134 - 139
  • [35] Estrogen receptor β in the breast:: role in estrogen responsiveness and development of breast cancer
    Gustafsson, JÅ
    Warner, M
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2000, 74 (05) : 245 - 248
  • [36] The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens
    Hall, JM
    McDonnell, DP
    [J]. ENDOCRINOLOGY, 1999, 140 (12) : 5566 - 5578
  • [37] Functional analysis of a novel estrogen receptor-β isoform
    Hanstein, B
    Liu, H
    Yancisin, MC
    Brown, M
    [J]. MOLECULAR ENDOCRINOLOGY, 1999, 13 (01) : 129 - 137
  • [38] Regulation of metallothionein II messenger ribonucleic acid measures exogenous estrogen receptor-β activity in SAOS-2 and LNCaPLN3 cells
    Harris, HA
    Henderson, RA
    Bhat, RA
    Komm, BS
    [J]. ENDOCRINOLOGY, 2001, 142 (02) : 645 - 652
  • [39] HENDERSON BE, 1988, CANCER RES, V48, P246
  • [40] Horvath LG, 2001, CANCER RES, V61, P5331